Bicycle Therapeutics has appointed a Chief Medical Officer.听
Dr. Dominic Smethurst has joined the Cambridge company, which is developing a novel class of medicines,听referred to as Bicycles, for diseases that are underserved by existing therapeutics.听
Dr. Smethurst brings听extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases.听
He has more than听20 years of experience working with leading pharmaceutical and biotechnology companies, clinical research institutions and the NHS.听
Among his previous roles are Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche.听听
鈥淕iven his in-depth knowledge of conventional and disruptive therapeutic modalities, we believe Dominic is uniquely qualified to guide development of Bicycles as potential solutions to many of the limitations faced by small molecule and antibody-based medicines,鈥� said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.听听
鈥淒ominic will be responsible for designing and driving execution of the clinical development plans for our pipeline candidates, all of which currently represent possible first-in-class or best-in-class therapies.听听
鈥淒ominic adds a critical capability to our senior leadership team, and we are pleased to welcome him to Bicycle.鈥�听
In June听Bicycle听announced the appointment of听Sir Keith Peters FRS听to听chairman of the听firm鈥檚 scientific听advisory听board.听听
Despite its Cambridge headquarters,听many key functions and members of its leadership team听are听located in听the US.听听听
听
medtech